Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引：1

作者：

Galsky, Matthew D. ^{[1
,2
]}

Daneshmand, Siamak ^{[3
]}

Izadmehr, Sudeh ^{[1
]}

Gonzalez-Kozlova, Edgar ^{[4
]}

Chan, Kevin G. ^{[5
]}

Lewis, Sara ^{[6
]}

El Achkar, Bassam ^{[6
]}

Dorff, Tanya B. ^{[7
]}

Cetnar, Jeremy Paul ^{[8
]}

Neil, Brock O. ^{[9
]}

D'Souza, Anishka ^{[10
]}

Mamtani, Ronac ^{[11
]}

Kyriakopoulos, Christos ^{[12
]}

Jun, Tomi ^{[13
,25
]}

Gogerly-Moragoda, Mahalya ^{[1
]}

Brody, Rachel ^{[2
,14
]}

Xie, Hui ^{[15
]}

Nie, Kai ^{[15
]}

Kelly, Geoffrey ^{[15
]}

Horowitz, Amir ^{[2
,16
]}

Kinoshita, Yayoi ^{[14
]}

Ellis, Ethan ^{[17
,18
]}

Nose, Yohei ^{[16
]}

Ioannou, Giorgio ^{[16
]}

Cabal, Rafael ^{[16
]}

Del Valle, Diane M. ^{[16
]}

Haines, G. Kenneth ^{[19
]}

Wang, Li ^{[1
,20
]}

Mouw, Kent W. ^{[21
]}

Samstein, Robert M. ^{[22
]}

Mehrazin, Reza ^{[23
]}

Bhardwaj, Nina ^{[2
,15
,16
]}

Yu, Menggang ^{[24
]}

Zhao, Qianqian ^{[24
]}

Kim-Schulze, Seunghee ^{[2
,15
,16
]}

Sebra, Robert ^{[2
,17
,18
]}

Zhu, Jun ^{[1
,20
]}

Gnjatic, Sacha ^{[2
,15
,16
]}

Sfakianos, John ^{[23
]}

Pal, Sumanta K. ^{[7
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[3] Keck Sch Med USC, Dept Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[4] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Tisch Canc Inst, New York, NY 10029 USA

[5] City Hope Comprehens Canc Ctr, Dept Urol, Duarte, CA USA

[6] Icahn Sch Med Mt Sinai, Dept Radiol, Tisch Canc Inst, New York, NY 10029 USA

[7] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[8] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

[9] Univ Utah, Dept Urol, Salt Lake City, UT USA

[10] Keck Sch Med USC, Div Hematol & Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[11] Univ Penn, Abramson Canc Ctr, Div Hematol & Med Oncol, Philadelphia, PA 19104 USA

[12] Univ Wisconsin, Div Hematol & Med Oncol, Carbone Canc Ctr, Madison, WI USA

[13] Genentech Inc, San Francisco, CA USA

[14] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pathol, New York, NY 10029 USA

[15] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA

[16] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA

[17] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[18] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA

[19] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based, New York, NY 10029 USA

[20] Gene Dx, Stamford, CT USA

[21] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA

[22] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, Tisch Canc Inst, New York, NY 10029 USA

[23] Icahn Sch Med Mt Sinai, Dept Urol, Tisch Canc Inst, New York, NY 10029 USA

[24] Univ Wisconsin, Carbone Canc Ctr, Dept Biostat & Med Informat, Madison, WI USA

[25] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 04期

关键词：

D O I：

10.1038/s41591-024-02814-0

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1211 / 1211

页数：1

共 50 条

[21] Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial
Anari, Fern
O'Neill, John
Choi, Woonyoung
Chen, David Y. T.
Haseebuddin, Mohammed
Kutikov, Alexander
Dulaimi, Essel
Alpaugh, R. Katherine
Devarajan, Karthik
Greenberg, Richard E.
Bilusic, Marijo
Wong, Yu-Ning
Viterbo, Rosalia
Hoffman-Censitsc, Jean H.
Lallas, Costas D.
Trabulsic, Edouard J.
Smaldone, Marc
Geynisman, Daniel M.
Zibelman, Matthew
Lin, Jianqing
Kelly, W. Kevin
Uzzo, Robert
McConkey, David
Plimack, Elizabeth R.
EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (01): : 54 - 60
[22] Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Xing, N.
Han, S.
Jiang, J.
Xu, W.
Shi, B.
Ping, H.
Ji, Z.
Ma, Q.
Wang, H.
Chen, S.
Wang, W.
Fan, X.
Zhou, Q.
Zhang, W.
ANNALS OF ONCOLOGY, 2021, 32 : S714 - S714
[23] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
Yafi, Faysal A.
Kassouf, Wassim
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
[24] Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials
Arcangeli, G.
Strigari, L.
Arcangeli, S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 387 - 396
[25] Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Iyer, Gopa
Balar, Arjun V.
Milowsky, Matthew I.
Bochner, Bernard H.
Dalbagni, Guido
Donat, S. Machele
Herr, Harry W.
Huang, William C.
Taneja, Samir S.
Woods, Michael
Ostrovnaya, Irina
Al-Ahmadie, Hikmat
Arcila, Maria E.
Riches, Jamie C.
Meier, Andreas
Bourque, Caitlin
Shady, Maha
Won, Helen
Rose, Tracy L.
Kim, William Y.
Kania, Brooke E.
Boyd, Mariel E.
Cipolla, Catharine K.
Regazzi, Ashley M.
Delbeau, Daniela
McCoy, Asia S.
Vargas, Hebert Alberto
Berger, Michael F.
Solit, David B.
Rosenberg, Jonathan E.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1949 - +
[26] Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
Matsubara, Nobuaki
Mukai, Hirofumi
Naito, Yoichi
Nezu, Masahiko
Itoh, Kuniaki
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 310 - 317
[27] Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
Li, Kaiwen
Zhong, Wenlong
Fan, Jinhai
Wang, Shaogang
Yu, Dexin
Xu, Tao
Lyu, Jiaju
Wu, Shaoxu
Qin, Tao
Wu, Zhuo
Xu, Longhao
Wu, Kaijie
Liu, Zheng
Hu, Zhiquan
Li, Fan
Wang, Jinyou
Wang, Qi
Min, Jie
Zhang, Zhiqiang
Yu, Luping
Ding, Sentai
Huang, Longfei
Zhao, Tingting
Huang, Jian
Lin, Tianxin
NATURE CANCER, 2024, 5 (10) : 1465 - 1478
[28] Organ-sparing Chemoradiotherapy: a viable Alternative to initial Cystectomy for patients with Muscle-invasive bladder cancer compared to Radiotherpay
Weiss, C.
Sauer, R.
STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 713 - 716
[29] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer
Chang, Sam S.
JOURNAL OF UROLOGY, 2020, 203 (04): : 659 - 660
[30] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer
Voskuilen, Charlotte S.
van der Heijden, Michiel S.
van Rhijn, Basw. G.
EUROPEAN UROLOGY, 2019, 76 (06) : 870 - 871

← 1 2 3 4 5 →